A study of a weight-adjusted aprotinin dosing schedule during cardiac surgery

Anesthesia and Analgesia

Volumn 94, Issue 2, 2002, Pages 283-289

  Nuttall, Gregory A ^a   Fass, David N ^a   Oyen, Lance J ^a   Oliver Jr , William C ^a   Ereth, Mark H ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD TRANSFUSION; BODY WEIGHT; CLINICAL ARTICLE; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HEART SURGERY; HUMAN; MALE; PRIORITY JOURNAL;

EID: 0036150488     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/00000539-200202000-00010     Document Type: Article

References (36)

1. Is ε-aminocaproic acid as effective as aprotinin in reducing bleeding with cardiac surgery? A meta-analysis
2. The economic impact of inappropriate blood transfusion in coronary artery bypass graft surgery
3. Comparison of bloodconservation strategies in cardiac surgery patients at high risk for bleeding
4. A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting
5. Tranexamic acid compared with high-dose aprotinin in primary elective heart operations: Effects on perioperative bleeding and allogeneic transfusions
6. Influence of high-dose aprotinin treatment on blood loss and coagulation patterns in patients undergoing myocardial revascularization
7. High-dose aprotinin therapy: A review of the first five years' experience
8. Is perioperative plasma aprotinin concentration more predictable and constant after a weight-related dose regimen?
9. Plasma aprotinin concentrations during cardiac surgery: Full- versus half-dose regimens
10. The impact of renal dysfunction on aprotinin pharmacokinetics during cardiopulmonary bypass
11. Influence of high-dose aprotinin on anticoagulation, heparin requirement, and celiteand kaolin-activated clotting time in heparin-pretreated patients undergoing open-heart surgery: A double blind, placebo-controlled study
12. Maintenance of therapeutic plasma aprotinin levels during prolonged cardiopulmonary bypass using a large-dose regimen
13. Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol)
14. Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass
15. Efficacy of a simple intraoperative transfusion algorithm for nonerythrocyte component utilization after cardiopulmonary bypass
16. Pharmacokinetics of aprotinin in preoperative cardiac surgical patients
17. Aprotinin reduces blood loss after cardiopulmonary bypass by direct inhibition of plasmin
18. Robust tests for the equality of variances
19. Aprotinin in cardiopulmonary bypass: Effects on the Hageman factor (FXII)-Kallikrein system and blood loss
20. Aprotinin versus lysine analogues: The debate continues
21. Aprotinin modulation of platelet activation in patients undergoing cardiopulmonary bypass operation
22. Clinical application of inhibitors of fibrinolysis
23. On the reaction of piasmin or piasmin-streptokinase complex with aprotinin or alpha 2-antiplasmin
24. Inhibitory effect of aprotinin and gabexate mesilate on human plasma kallikrein
25. Effect of intraoperative aprotinin administration on postoperative bleeding in patients undergoing cardiopulmonary bypass operation
26. Aprotinin prevents bleeding and has effects on platelets and fibrinolysis
27. Randomized placebocontrolled double-blind study of three aprotinin regimens in primary cardiac surgery
28. Influence of high- and low-dose aprotinin on activation of hemostasis in open-heart operations
29. Aprotinin: Safe and effective only with the full-dose regimen
30. Analyses of coronary graft patency after aprotinin use: Results from the international muiticenter aprotinin graft patency experience (IMAGE) trial
31. Pharmacokinetics of dopamine in healthy male subjects
32. Effects of cardiopulmonary bypass on vancomycin plasma concentration decay
33. Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs
34. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety
35. Comparison of a weight-based heparin nomogram with traditional heparin dosng to achieve therapeutic anticoagulation